Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Reduced amplification efficiency of the RNA-dependent-RNA-polymerase target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests

Ziyaad Valley-Omar, Gert Marais, Arash Iranzadeh, Michelle Naidoo, Stephen Korsman, Tongai Maponga, Hannah Hussey, Mary-Ann Davies, Andrew Boulle, Deelan Doolabh, Mariska Laubscher, Justyna Wojno, J.D. Deetlefs, Jean Maritz, Lesley Scott, Nokukhanya Msomi, Cherise Naicker, Houriiyah Tegally, Tulio de Oliveira, Jinal Bhiman, Carolyn Williamson, Wolfgang Preiser, Diana Hardie, Nei-yuan Hsiao, Stephen Korsman, Deelan Doolabh, Mariska Laubscher, Justyna Wojno, J.D. Deetlefs, Jean Maritz, Lesley Scott, Nokukhanya Msomi, Cherise Naicker, Houriiyah Tegally, Tulio de Oliveira, Jinal Bhiman, Carolyn Williamson, Wolfgang Preiser, Diana Hardie, Nei-yuan Hsiao.

Keywords: SARS-CoV-2, COVID-19, Delta variant, Diagnostic test, South Africa, Surveillance

Abstract

Routine SARS-CoV-2 surveillance in the Western Cape region of South Africa (January-August 2021) found a reduced RT-PCR amplification efficiency of the RdRp-gene target of the Seegene, Allplex 2019-nCoV diagnostic assay from June 2021 when detecting the Delta variant. We investigated whether the reduced amplification efficiency denoted by an increased RT-PCR cycle threshold value (RΔE) can be used as an indirect measure of SARS-CoV-2 Delta variant prevalence. We found a significant increase in the median RΔE for patient samples tested from June 2021, which coincided with the emergence of the SARS-CoV-2 Delta variant within our sample set. Whole genome sequencing on a subset of patient samples identified a highly conserved G15451A, non-synonymous mutation exclusively within the RdRp gene of Delta variants, which may cause reduced RT-PCR amplification efficiency. While whole genome sequencing plays an important in identifying novel SARS-CoV-2 variants, monitoring RΔE value can serve as a useful surrogate for rapid tracking of Delta variant prevalence.

Genomic surveillance of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by whole genome sequencing (WGS) has played a critical role in monitoring the dissemination of variants of concern (VOCs) (Abdool Karim and de Oliveira, 2021; WHO, 2021). However, WGS is costly and time-consuming, and not all countries have the resources to do this at scale to get detailed VOC epidemiological information.

Multiplex reverse transcriptase polymerase chain reaction (RT-PCR)-
based diagnostic tests for SARS-CoV-2, which simultaneously amplify and detect multiple SARS-CoV-2 gene targets, such as the Spike (S)-, Nucleocapsid (N)-, Envelope (E)- and RNA-dependent-RNA-polymerase (RdRp) genes, are the primary tools used to diagnose cases and define epidemic waves. Current commercial tests were designed to detect ancestral SARS-CoV-2 sequences and have not been optimised for the viral genomic diversity that has subsequently emerged (WHO, 2020). Despite this, built-in redundancy through detecting multiple gene targets ensures that these assays continue to be effective tools for diagnosing infections by contemporary variants as diagnostic assays do not need to detect all target genes. For example, deletions of amino acids 69 and 70 within the S-gene of SARS-CoV-2 Alpha and Omicron variants was associated with failure to detect this target by some commonly used commercial diagnostic assays (e.g. ThermoFisher TaqPath, Waltham, USA). Fortunately, because the other targets are largely unaffected, this S-gene target failure (S-GTF) has been used as a convenient surrogate marker for monitoring prevalence of SARS-CoV-2 Alpha variant (Brown et al., 2021; Volz et al., 2021).

As the Delta variant becomes the predominant VOC across the world, a similar diagnostic RT-PCR-based marker has potential to enable similar rapid epidemiological assessment and research. An evaluation of routine diagnostic results together with WGS, we show that infection with the Delta variant is associated with reduced RdRp target amplification efficiency and propose that this can be used for tracking the prevalence of this variant.

Routine SARS-CoV-2 diagnostic testing in the South African public health sector, which is used by circa 80 % of the population is performed by the National Health Laboratory Service (NHLS). NHLS laboratories also form part of the network for genomic surveillance South Africa (NGS-SA) where a subset of routine diagnostic samples are sequenced as part of the genomic surveillance activities (Msomi et al., 2020), WGS was performed using either GridION X5 (Oxford Nanopore Technologies, Oxford, United Kingdom) or MiSeq (illumina, San Diego, USA) sequencing platforms (Tegally et al., 2021). To ensure accurate clade assignment, we only included sequences with less than 3000 bases missing, no frameshift mutations and no misplaced stop codons. All sequences were deposited on the Global Initiative on Sharing All Influenza Data (GISAID) SARS-CoV-2 sequence repository (https://www.gISAID.org/) (Supplementary Table 1).

Between March 2020 and August 2021, the Seegene Allplex 2019-nCoV assay (Seegene, Allplex 2019-nCoV) is a single-tube multiplex assay with three SARS-CoV-2 gene targets: E, RdRp and N, was one of the most commonly used RT-PCR platforms across the NHLS. From May 2021, we observed a consistent increase in the number of samples testing positive with the Seegene Allplex nCoV-19 assay that had either delayed or absent RdRp target detection (cycle threshold (CT) value) relative to E gene and N gene targets. Prior to this period, the average difference between the CT values for RdRp and E-gene targets (ΔE) was around 2. From June 2021, the ΔE in diagnostic samples increased to a median of 5 (Fig. 1). We investigated if the efficiency of RdRp target amplification and detection was affected by mutations in the predominant circulating variant.

The Western Cape province where the study was conducted, entered its third epidemic wave on 21 June 2021 (week 25), with more than 1020 cases reported daily and >20 % week-on-week increase in the 7-day moving average of new cases. During the same period, genomic surveillance data showed a rapid increase in Delta variant infection, which rapidly replaced Beta as the predominant VOC in the region (Fig. 2). As the cases surged, the proportion of Delta variant increased from just over 20 % of total samples sequenced in May 2021, to >90 % in August 2021. To investigate the observed RdRp target delay which coincided with the emergence of Delta, RdRp gene sequences of samples tested with the Seegene, Allplex 2019-nCoV assay were evaluated for mutations that could interfere with RT-PCR probe or primer binding. We identified a non-synonymous G15451A mutation (codon 671S) within RdRp gene of

Delta variants, potentially responsible for the reduced amplification efficiency of the assay RdRp target. This highly conserved G15451A mutation was present in 100 % (369/369) of Delta variant sequences and not observed in Alpha (n = 11), Beta (n = 749) or Eta (n = 5) variants sequenced between March 2020 and 19 August 2021 (Supplementary Fig. 1). In addition, we previously found that a synonymous G15452C mutation (codon 671S) in a minority of Beta variant sequences (‘-end of this forward primer binding site) also affected RdRp gene target detection when using the Seegene, Allplex 2019-nCoV assay (Supplementary Fig. 1).

To systematically assess the effect of this Delta variant G15451A mutation on Seegene assay RdRp target amplification efficiency relative to that of ancestral strain and Beta variant, we compared the median relative RdRp and E gene target Ct values (R&E) among the different World Health Organisation SARS-CoV-2 designated variants detected in diagnostic samples over this time period. Of the 1455 sequences retrieved, 39 sequences with incomplete Ct data was removed, leaving 9, 731, 362 and 314 were Alpha, Beta, Delta and other variants respectively. Delta variant samples had a significantly increased R&E (n = 362, median = 5.74, Interquartile range (IQR) 4.76-6.55) when compared to non-Delta variant samples (n = 1056, median = 2.54, IQR 2.13-3, p < 0.001) (Supplementary Fig. 2). The diagnostic ability of the R&E value to identify the Delta variant was evaluated using a receiver operating characteristic (ROC) curve (Supplementary Fig. 3). Using a R&E threshold of > 3.5 cycles we were able to accurately identify Delta variant positive samples within the sample set with 93.6 % sensitivity and 89.7 % specificity, correctly classifying 90 % of cases (Area under the curve (AUC) = 0.9663). When the threshold is increased to 4 and 4.5 cycles, the specificity was improved to 96.5 % and 98 % respectively but the sensitivity was reduced to 86.7 % and 80 % respectively.

In this article we show that reduced amplification efficiency of the RdRp gene target of the Seegene, Allplex 2019-nCoV assay can be used as an indirect measure of SARS-CoV-2 Delta variant prevalence in a population. Using the R&E value could therefore serve as a reliable surrogate for genomic sequencing to approximate the spread of the SARS-CoV-2 Delta variant. While using the R&E is only a surrogate marker of Delta variant identity, assay Ct values have proven useful in the past to identify Alpha variant prevalence as well as serving as an
independent predictor of disease severity (Yu et al., 2020; Choudhuri et al., 2020). Limitations to our study concern the proprietary nature of the Seegene, Allplex 2019-nCoV assay. We are unable to confirm the exact genomic loci amplified by the assay primers and probes. Evidence including the RdRp target delay in Delta variants from this study, RdRp complete GTF in a minority of Beta variants and confirmation by Seegene that the G15451A mutation in Delta variants leads to a mismatch in the primer binding site, suggest that these diagnostic primers overlap with the WHO-recommended RT-PCR primer sets stemming from Corman et al., 2020 (Corman et al., 2020). This study highlights the need for continued monitoring of the efficacy of current commercial SARS-CoV-2 diagnostic assays in a setting where we are observing the constant genetic drift of a novel pathogen.

Author statement

Ziyaad Valley-Omar: Conceptualization; Methodology; Formal analysis; Investigation; Writing.
Gert Marais: Methodology; Formal analysis; Investigation; Writing.
Arash Iranzadeh: Methodology; Investigation; Writing
Michelle Naidoo: Methodology; Investigation; Writing
Stephen Korsman: Investigation; Resources; Writing
Tongai Maponga: Formal analysis; Investigation; Writing.
Hannah Hussey: Conceptualization; Formal analysis; Investigation; Resources; Writing.
Mary-Ann Davies: Resources; Writing.
Andrew Boulle: Resources; Writing.
Deelan Doolabh: Methodology; Investigation; Writing.
Mariska Laubscher: Resources; Writing.
Justyna Wojno: Resources; Writing.
JD Deetlefs: Resources; Writing.
Jean Maritz: Resources; Writing.
Lesley Scott: Resources; Writing.
Nokukhanya Msomi: Resources; Writing.
Cherise Naicker: Resources; Writing.
Houriiyah Tegally: Methodology; Writing
Tulio de Oliveira: Methodology; Resources; Writing.
Jinal Bhiman: Conceptualization; Methodology; Resources; Writing.
Carolyn Williamson: Resources; Writing
Wolfgang Preiser: Resources; Writing.
Diana Hardie: Conceptualization; Formal analysis; Investigation; Writing.
Nei-yuan Hsiao: Conceptualization; Formal analysis; Investigation; Resources; Writing.

Funding statement

This research was funded in whole, or in part, by the Wellcome Trust [222574/Z/21/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The Wellcome Centre for Infectious Diseases Research in Africa is supported by core funding from the Wellcome Trust [230135/Z/16/Z]. This research was also supported by the Grand Challenges ICODA pilot initiative delivered by Health Data Research UK funded by the Bill & Melinda Gates and the Minderoo Foundations, and by a research Flagship grant from the South African Medical Research Council (MRC-RFA-UFSF-01-2013/UKZN HIVEPI).

Disclaimers

The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the funding agencies.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data availability

Data will be made available on request.

Acknowledgments

We gratefully acknowledge the efforts of the staff of the NHLS and University of Cape Town (Nokuzola Mbhele, Fezokuhle Khumalo, Thabang Serakge and Innocent Mudau) laboratories responsible for obtaining the specimens. This study is an extension to current genomic surveillance activity of Network for Genomic Surveillance in South Africa (NGS-SA) and forms part of the “Molecular Surveillance of SARS-CoV-2 in the Western Cape: Understanding Spread to Inform Intervention Strategies” study within the UCT Division of Medical Virology. Study protocols have been approved by the UCT Faculty of Health Sciences Human Research Ethics Committee (HREC:383/2020).
Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.jviromet.2022.114471.

References

Abdool Karim, S.S., de Oliveira, T., 2021. New SARS-CoV-2 variants - clinical, public health, and vaccine implications. N. Engl. J. Med. 1866–1868.

Brown, K.A., Gubbay, J., Hopkins, J., et al., 2021. S-gene target failure as a marker of variant B.1.1.7 among SARS-CoV-2 isolates in the greater toronto area, December 2020 to March 2021. Jama (325), 2115–2116.

Choudhuri, J., Carter, J., Nelson, R., et al., 2020. SARS-CoV-2 PCR cycle threshold at hospital admission associated with patient mortality. PLoS One 15, e0244777.

Corman, V.M., Landt, O., Kaiser, M., et al., 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro surveillance: bulletin European sur les maladies transmissibles – European communicable disease bulletin (25), 23–30.

Msomi, N., Mlisana, K., de Oliveira, T., 2020. Network for Genomic Surveillance in South Africa writing g. A genomics network established to respond rapidly to public health threats in South Africa. Lancet Microbe 1 e229–e30.

Tegally, H., Wilkinson, E., Giovanetti, M., et al., 2021. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438–443.

Volz, E., Mishra, S., Chand, M., et al., 2021. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature 593, 266–269.

WHO, 2020. WHO Inhouse Assays.

WHO, 2021. Tracking SARS-CoV-2 Variants.

Yu, F., Yan, L., Wang, N., et al., 2020. Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients. Clin. Infect. Dis. 71, 793–798.